Recombinant Vaccines Market

Recombinant vaccines are produced using recombinant DNA technology, with the help of a vector. These vaccines stimulate the immune system of an individual and provide immunity against various lethal disease.

These vaccines are safe and have less or no side-effects as compared to conventional vaccines, in the prevention of various diseases such as influenza, cholera, typhoid, and dengue.

Recombinant vaccines are also used in animals for prevention of diseases such as foot and mouth disease, pneumonia and septicemia, and pox disease. Vaccination results in the prevention of disease, by producing antibodies against the protein antigen of pathogenic microorganisms.

Recombinant Vaccines Market contains market size and forecasts of Recombinant Vaccines in global, including the following market information:

Global Recombinant Vaccines Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Recombinant Vaccines Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Recombinant Vaccines companies in 2021 (%)

The global Recombinant Vaccines market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Subunit Recombinant Vaccines Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Recombinant Vaccines include Merck & Co., Inc, Green Cross Corporation, Pfizer Inc., Bayer AG, Sanofi S A., Protein Science Corporation, GlaxoSmithKline Plc., Novartis AG and Bharat Biotech. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Recombinant Vaccines manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Recombinant Vaccines Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Recombinant Vaccines Market Segment Percentages, by Type, 2021 (%)

Subunit Recombinant Vaccines

Attenuated Recombinant Vaccines

Vector Recombinant Vaccines

Global Recombinant Vaccines Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Recombinant Vaccines Market Segment Percentages, by Application, 2021 (%)

Recombinant Human Vaccines

Animal Recombinant Vaccines

Global Recombinant Vaccines Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Recombinant Vaccines Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Recombinant Vaccines revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Recombinant Vaccines revenues share in global market, 2021 (%)

Key companies Recombinant Vaccines sales in global market, 2017-2022 (Estimated), (K Units)

Key companies Recombinant Vaccines sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Merck & Co., Inc

Green Cross Corporation

Pfizer Inc.

Bayer AG

Sanofi S A.

Protein Science Corporation

GlaxoSmithKline Plc.

Novartis AG

Bharat Biotech